NovoCure (NVCR) Return on Capital Employed (2015 - 2026)
NovoCure (NVCR) posted quarterly Return on Capital Employed of 27.05% for Q2 2026, up 767.0% year-on-year from 3.12% in Q2 2025, and up 14.66% on a QoQ basis from 31.69% in Q1 2026.
NovoCure (NVCR) Return on Capital Employed (2015 - 2026) Analysis & Trends
NovoCure (NVCR) has reported Return on Capital Employed for 12 consecutive years, with 27.05% the latest figure, recorded in Q2 2026.
- Quarterly Return on Capital Employed rose 767.0% year-over-year to 27.05% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 27.05% (up 767.0% YoY) and the FY2025 annual result came in at 19.24%, up 1977.0% from the prior year.
- Return on Capital Employed rose to 27.05% in Q2 2026 per NVCR's latest filing, from 31.69% in the prior quarter.
- Over the last five years, Return on Capital Employed for NVCR reached as high as 4.43% in Q1 2022 and fell as low as 35.89% in Q4 2024.
- A 5-year average of 21.81% and a median of 22.25% in 2023 frame the typical range for Return on Capital Employed.
- The largest YoY upside for Return on Capital Employed was 1800 bps in 2025 against a maximum downside of 1617 bps in 2025.
- Year by year, Return on Capital Employed stood at 8.74% in 2022, then slumped by 175 bps to 24.08% in 2023, then tumbled by 49 bps to 35.89% in 2024, then soared by 50 bps to 17.89% in 2025, then tumbled by 51 bps to 27.05% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 27.05%, 31.69%, and 17.89% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.86 Bn | 175.56 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 128.95 Bn | 126.07 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 108.31 Bn | 99.09 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 68.46 Bn | 67.01 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 48.25 Bn | 44.58 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 28.35 Bn | 27.23 Bn | 750.30 Mn | 24.24% |
| 7 | GE HealthCare Technologies | 28.05 Bn | 25.76 Bn | 1.98 Bn | 9.30% |
| 8 | Smith & Nephew | 26.96 Bn | 26.38 Bn | - | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | 8.38% |
| 10 | NovoCure | 2.01 Bn | 1.57 Bn | 142.48 Mn | -27.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.05% |
| Mar 31, 2026 | -31.69% |
| Dec 31, 2025 | -17.89% |
| Sep 30, 2025 | -33.50% |
| Jun 30, 2025 | -34.72% |
| Mar 31, 2025 | -33.27% |
| Dec 31, 2024 | -35.89% |
| Sep 30, 2024 | -32.96% |
| Jun 30, 2024 | -18.55% |
| Mar 31, 2024 | -22.00% |
| Dec 31, 2023 | -24.08% |
| Sep 30, 2023 | -22.51% |
| Jun 30, 2023 | -18.74% |
| Mar 31, 2023 | -14.40% |
| Dec 31, 2022 | -8.74% |
| Sep 30, 2022 | -6.81% |
| Jun 30, 2022 | -5.28% |
| Mar 31, 2022 | -4.43% |
| Dec 31, 2021 | -4.49% |
| Sep 30, 2021 | -0.90% |